Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement - Seite 2

“Abingworth is thrilled to enter this strategic development funding agreement with Teva around its exciting ICS-SABA (TEV-‘248) program. It is another great example of where we can put capital to work, alongside the operational expertise of Launch Therapeutics, to seek to accelerate the late-stage clinical development of a highly promising program towards patients in need of new therapies,” commented Bali Muralidhar, Managing Partner, Chief Investment Officer & COO at Abingworth.

Notes for Editors

About ICS/SABA – fluticasone/albuterol (TEV-‘248)

Short-Acting Beta-Agonists (SABAs) are used for the treatment of asthma symptoms providing rapid relief. SABAs do not address the underlying inflammation, which can lead to SABA overuse and poor clinical outcomes, including a correlation with increased mortality. This evidence has led the Global Initiative for Asthma (GINA) to stop recommending the use of SABA alone for patients with asthma. Instead, combining SABA with Inhaled Corticosteroids (ICS) is safer and more effective, addressing both immediate symptoms and long-term inflammation, leading to improved asthma management, including a significant reduction in the risk of severe exacerbations (asthma attacks). Teva’s albuterol/fluticasone combination (TEV-‘248) is currently in Phase 3 clinical trials to demonstrate a reduction in severe exacerbations compared to reliever treatment with SABA alone (Study FpA-AS-30094) and the airway relaxation effect of albuterol in the combination product (Study FpA-AS-30093).

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.